Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Gene Panel Tests for Hundreds of Diseases Simultaneously

By Labmedica International staff writers
Posted on 16 Dec 2013
Image: The HiSeq 2000 sequencing system (Photo courtesy of Illumina).
Image: The HiSeq 2000 sequencing system (Photo courtesy of Illumina).
A new genetic sequencing test moves beyond assaying for one disease at a time, making it possible to identify more than 750 diseases triggered by mutations in children concomitantly and deliver results within six to eight weeks.

Currently, most genetic tests for childhood diseases are conducted one at a time, and this trial-and-error process consumes valuable time for clinicians in the search for the most effective treatment options for their patients and for families and the healthcare system, the prolonged hunt means higher costs.

Scientists at Children's Mercy Hospital (Kansas City, MO, USA) developed a screening panel, called the Targeted Gene Sequencing and Custom Analysis (TaGSCAN) that covers the 514 genetic regions that code for pediatric conditions with possible hereditary or elusive diagnoses. TaGSCAN is a hybrid of hypothesis-based and non-hypothesis-based testing. In a study involving 107 patients with neurodevelopmental disorders, 40 of these patients received new diagnoses as a result of the test. There were 10 cases where diagnosis was directly attributed to starting new treatments, discontinuing unnecessary medications or avoiding invasive procedures.

One advantage of the new test is that it can be ordered routinely. It has been used in over 180 patients at Children's Mercy since it was introduced in January 2013. The test looks at the genetic history of the patient's family, tests large numbers of genes, and combines the data with bioinformatic analysis. The test is highly sensitive, detecting approximately 95% of known genetic mutations in more than 750 diseases. Most of the genes on the panel are autosomal recessive, with few exceptions. The panel is rich in genes for neurodevelopmental, metabolic, nuclear mitochondrial, intellectual disability, and immunodeficiency conditions.

Stephen Kingsmore, MB ChB, DSc, director of the center for Pediatric Genomic Medicine at Children's Mercy, said, “There are about 7,000 diseases caused by single-gene mutations, about half of which have identified genetic causes. Genetic testing in critically ill babies might be able to identify the cause, but prior to development of this new approach, gene sequencing took too long, cost too much, and the findings were too complicated for practical use. This new diagnostic system currently includes signs and symptoms for 595 single-gene diseases for which the causes are known.” The study was presented at the 63rd Annual Meeting of the American Society Genomics (ASHG) held October 22–26, 2013, in Boston (MA, USA).

Related Links:

Children's Mercy Hospital



DRG International
DiagCor Bioscience
77 ELEKTRONIKA
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The gel zymography separation of matrix metalloproteinases (MMPs) on a 7.5% polyacrylamide gel (Photo courtesy of the Italian National Research Council).

Quantitative Gel Zymography Reappraised for Matrix Metalloproteinases

A reappraisal of quantitative gel zymography technique for matrix metalloproteinases (MMPs) in human plasma has been used for comparison with commercially available enzyme-linked immunosorbent assay (ELISA).... Read more

Industry News

view channel

French-German Cooperation to Improve Personalized Cancer Care

A leading French oncology center will be collaborating with a German manufacturer of molecular diagnostic tests to develop new approaches to personalized cancer care. The Gustave Roussy Cancer Campus (Paris, France), a medical center with 2,600 health professionals dedicated to cancer diagnosis and treatment that devotes... Read more
 

Events

06 Nov 2014 - 08 Nov 2014
12 Nov 2014 - 15 Nov 2014
Copyright © 2000-2014 Globetech Media. All rights reserved.